临床试验/IRCT20200105046010N41

IRCT20200105046010N41招募中未知

In- Vivo Bioequivalence study of Rosuvastatin tablet 20mg Kharazmi with brand drugs (CRESTOR® 20mg, Astra-Zeneca, Belgium) in Iranian healthy volunteers

Kharazmi Pharmaceutical Co0 个研究点目标入组 24 人开始时间: 待定最近更新: 2021年11月1日

试验速览

阶段: 未知
状态: 招募中
发起方: Kharazmi Pharmaceutical Co
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 60 years（—）
性别: All

入选标准

•General health
•Body mass index between18-28
•Informed consent
•Being at the age of 18-60 years old

排除标准

•A history of cardiovascular disease
•A history of liver & kidney disease
•Alcohol & Drug addiction
•Hypersensitivity to the drug

研究者

发起方

Kharazmi Pharmaceutical Co

相似试验

In-vivo Bioequivalence Test of Rosuvastatin tablets with brand name drug CRESTOR® 20mg F.C Tab. Made by ASTRA-Zeneca, UK in Iranian healthy volunteers.

IRCT20200105046010N11Tabriz University of Medical Sciences24

Bioequivalence study of Rosuvastatin 40 mg tablet in 24 healthy male under fasting conditions

IRCT20180620040164N25Karen Pharma and Food Supplement Co.24

Bioequivalence study of Rosuvastatin 40 mg tablet in 24 healthy male under fasting conditions

IRCT20180620040164N22Dorsa Pharmaceutical Co.24

In- Vivo Bioequivalence study of Atorvastatin tablets 40 mg Kharazmi Pharma with brand drugs (LIPITOR® 40 mg, Pfizer, Germany) in Iranian healthy volunteers.

IRCT20200105046010N72Kharazmi Pharmaceutical Co.24

In-vivo Bioequivalence Test of Atorvastatin® tablet with brand drugs (LIPITOR® 100mg, Pfizer, Germany).

IRCT20200105046010N33Razak Pharma24